Cargando…
Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889263/ https://www.ncbi.nlm.nih.gov/pubmed/31363170 http://dx.doi.org/10.1038/s41416-019-0534-2 |
| _version_ | 1783475378267881472 |
|---|---|
| author | Evans, Thomas R. Jeffry Kudo, Masatoshi Finn, Richard S. Han, Kwang-Hyub Cheng, Ann-Lii Ikeda, Masafumi Kraljevic, Silvija Ren, Min Dutcus, Corina E. Piscaglia, Fabio Sung, Max W. |
| author_facet | Evans, Thomas R. Jeffry Kudo, Masatoshi Finn, Richard S. Han, Kwang-Hyub Cheng, Ann-Lii Ikeda, Masafumi Kraljevic, Silvija Ren, Min Dutcus, Corina E. Piscaglia, Fabio Sung, Max W. |
| author_sort | Evans, Thomas R. Jeffry |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6889263 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-68892632019-12-04 Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma Evans, Thomas R. Jeffry Kudo, Masatoshi Finn, Richard S. Han, Kwang-Hyub Cheng, Ann-Lii Ikeda, Masafumi Kraljevic, Silvija Ren, Min Dutcus, Corina E. Piscaglia, Fabio Sung, Max W. Br J Cancer Correction Nature Publishing Group UK 2019-07-30 2019-10-01 /pmc/articles/PMC6889263/ /pubmed/31363170 http://dx.doi.org/10.1038/s41416-019-0534-2 Text en © The Author(s) 2019 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correction Evans, Thomas R. Jeffry Kudo, Masatoshi Finn, Richard S. Han, Kwang-Hyub Cheng, Ann-Lii Ikeda, Masafumi Kraljevic, Silvija Ren, Min Dutcus, Corina E. Piscaglia, Fabio Sung, Max W. Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma |
| title | Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma |
| title_full | Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma |
| title_fullStr | Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma |
| title_full_unstemmed | Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma |
| title_short | Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma |
| title_sort | correction: urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 reflect study of lenvatinib vs sorafenib in hepatocellular carcinoma |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889263/ https://www.ncbi.nlm.nih.gov/pubmed/31363170 http://dx.doi.org/10.1038/s41416-019-0534-2 |
| work_keys_str_mv | AT evansthomasrjeffry correctionurineproteincreatinineratiovs24hoururineproteinforproteinuriamanagementanalysisfromthephase3reflectstudyoflenvatinibvssorafenibinhepatocellularcarcinoma AT kudomasatoshi correctionurineproteincreatinineratiovs24hoururineproteinforproteinuriamanagementanalysisfromthephase3reflectstudyoflenvatinibvssorafenibinhepatocellularcarcinoma AT finnrichards correctionurineproteincreatinineratiovs24hoururineproteinforproteinuriamanagementanalysisfromthephase3reflectstudyoflenvatinibvssorafenibinhepatocellularcarcinoma AT hankwanghyub correctionurineproteincreatinineratiovs24hoururineproteinforproteinuriamanagementanalysisfromthephase3reflectstudyoflenvatinibvssorafenibinhepatocellularcarcinoma AT chengannlii correctionurineproteincreatinineratiovs24hoururineproteinforproteinuriamanagementanalysisfromthephase3reflectstudyoflenvatinibvssorafenibinhepatocellularcarcinoma AT ikedamasafumi correctionurineproteincreatinineratiovs24hoururineproteinforproteinuriamanagementanalysisfromthephase3reflectstudyoflenvatinibvssorafenibinhepatocellularcarcinoma AT kraljevicsilvija correctionurineproteincreatinineratiovs24hoururineproteinforproteinuriamanagementanalysisfromthephase3reflectstudyoflenvatinibvssorafenibinhepatocellularcarcinoma AT renmin correctionurineproteincreatinineratiovs24hoururineproteinforproteinuriamanagementanalysisfromthephase3reflectstudyoflenvatinibvssorafenibinhepatocellularcarcinoma AT dutcuscorinae correctionurineproteincreatinineratiovs24hoururineproteinforproteinuriamanagementanalysisfromthephase3reflectstudyoflenvatinibvssorafenibinhepatocellularcarcinoma AT piscagliafabio correctionurineproteincreatinineratiovs24hoururineproteinforproteinuriamanagementanalysisfromthephase3reflectstudyoflenvatinibvssorafenibinhepatocellularcarcinoma AT sungmaxw correctionurineproteincreatinineratiovs24hoururineproteinforproteinuriamanagementanalysisfromthephase3reflectstudyoflenvatinibvssorafenibinhepatocellularcarcinoma |